StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)

StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research note published on Wednesday. The firm issued a sell rating on the stock.

Trinity Biotech Stock Performance

Shares of NASDAQ TRIB opened at $0.71 on Wednesday. The firm has a 50 day moving average price of $0.65 and a two-hundred day moving average price of $0.98. The stock has a market cap of $12.78 million, a P/E ratio of -0.31 and a beta of 1.21. Trinity Biotech has a 52-week low of $0.48 and a 52-week high of $3.55.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC grew its stake in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 378,590 shares of the company’s stock after buying an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 78.97% of the company’s stock.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.